Correlation between GLP-1 and CRP in patients with diabetic cardiomyopathy

( views:, downloads: )
Author:
JIN Ai-Ping(Second Clinical Hospital,Xi'an Jiaotong University)
XU Chen(Xi'an Second Hospital)
ZHANG Sui-Long(Second Clinical Hospital,Xi'an Jiaotong University)
Journal Title:
JOURNAL OF THE FOURTH MILITARY MEDICAL UNIVERSITY
Issue:
Volume 30, Issue 24, 2009
DOI:
Key Word:
diabetic cardiomyopathy;glucagon like peptides-1;hyper sensitive C-reactive protein

Abstract: AIM:To investigate the correlation between glucagon like peptides-1(GLP-1)and inflammatory cytokines and evaluate mechanism of diabetic cardiomyopathy.METHODS:Serum GLP-1,hyper sensitive C-reactive protein(hs-CRP),interleukin6(IL-6),tumor necrosis factor-α(TNF-α),blood pressure,fasting plasma glucose,2 h plasma glucose(2hPG),fasting serum insulin(FINS)and homeostasis model assessment insulin resistance(HOMA-IR)were measured in 50 patients with diabetic cardiomyopathy(experimental group)and 30 healthy persons(control group).RESULTS:Compared with control group,fasting plasma glucose,2hPG,systolic pressure,FINS,HOMA-IR,hs-CRP,IL-6 and TNF-α were significantly increased(P<0.05),while serum GLP-1 were reduced in experimental group(P<0.05);serum GLP-1 were negatively correlated with hs-CRP(r=0.556,P=0.1302)and HOMA-IR(r=0.445,P=0.007).CONCLUSION:The occurance and development of diabetic cardiomyopathy is decided by interrelation of GLP-1,inflammatory cytokines and insulin resistance.

  • [1]Asghar O,Al-Sunni A,Khavandi K.Diabetic cardiomyopathy[J].Clin Sci,2009,116(10):741-760.
  • [2]谭毅,王越晖,李校堃,等.心脏炎症反应在糖尿病心肌病发生发展中的病理作用[J].中国糖尿病杂志,2008,16(4):250-256.
  • [3]De Block CE,Van Gaal LF.GLP-1 receptor agonists for type 2 diabetes[J].Lancet,2009,374(9683):4-6.
  • [4]Harmancey R,Taegtmeyer H.The complexities of diabetic cardiomyopathy:lessons from patients and animal models[J].Carr Diab Rep,2008,8(3):243-248.
  • [5]Drimal J,Knezl V,Navarova J.Role of inflanmaatory cytokines and chemoattractants in the rat model of streptozotocin-induced diabetic heart failure[J].Endocr Regul,2008,42(4):129-135.
  • [6]Westermann D,Van Linthout S,Dhayat S.Cardioproteetive and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic eardiomyopathy[J].Diabetes,2007,56(7):1834-1841.
  • [7]沙伟伟,谢云.胰高血糖素样肽1的研究[J].医学综述,2008,14(1):24-26.
  • [8]Vaidya HB,Goyal RK.Glueagon like peptides-1 modulators as newer target for diabetes[J].Curr Drug Targets,2008,9(10):911-920.
  • [9]Sulistio M,Carothers C,Mangat M.GLP-1 agonist-based therapies:an emerging new class of antidiabetic drug with potential cardioprotective effects[J].Curt Atheroscler Rep,2009,11(2):93-99.
  • [10]Avogaro A.Glucagon-like peptide-1:Pleiotropic effects on the cardiovascular system[J].G hal Cardiol,2008,9(11):753-758.
  • [11]Mannucci E,Rotella CM.Future perspectives on glueagon-like peptide-1,diabetes and cardiovascular risk[J].Nutr Metab Cardiovasc Dis,2008,18(9):639-645.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn